Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01014936 · ClinicalTrials.gov registry record · Phase 1
First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors
A Phase 1 study of Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 1
- Development phase
- 149
- Enrollment target
- 1
- Study location
NCT01014936 is a Phase 1 study of Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available that has completed, run by EMD Serono. The registered enrollment target is 149 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01014936, a Phase 1 study of Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 149 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a an open-label, dose-escalation, first-in-man (FIM) study designed to explore MSC2156119J, in subjects with advanced solid tumors who have not responded to previous therapies or for whom no other therapies are available. Subjects will be assigned one of the dosing regimens: * Regimen 1: MSC2156119J once daily for 14 days, followed by 7 days with no treatment (21-day cycle) * Regimen 2: MSC2156119J three times per week (e.g., Days 1, 3, and 5) for three weeks (21-day cycle) * Regimen 3: MSC2156119J every day for three weeks (21-day cycle)
Conditions Studied
Interventions
- DRUG MSC2156119J
Study Locations (1)
Texas
- M.D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2009-11-30 |
| Est. Completion | 2015-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01014936
The ClinicalTrials.gov registry entry for NCT01014936 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available appearing as the primary indexed condition, and to 1 intervention - of which MSC2156119J is the first listed.
NCT01014936 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01014936 about?
NCT01014936 is a clinical study titled "First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors". This is a an open-label, dose-escalation, first-in-man (FIM) study designed to explore MSC2156119J, in subjects with advanced solid tumors who have not responded to previous therapies or for whom no other therapies are available. Subjects will be assigned one of the dosing regimens: * Regimen 1: M...
What is the current status of trial NCT01014936?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 149 participants. The study started on 2009-11-30. Estimated completion is 2015-10-31.
What conditions does trial NCT01014936 study?
This clinical trial studies the following conditions: Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available.
What interventions are being tested in trial NCT01014936?
The interventions under investigation include: MSC2156119J (DRUG).
Who is sponsoring clinical trial NCT01014936?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01014936 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.